We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Soars 10.0%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Teladoc (TDOC - Free Report) shares rallied 10% in the last trading session to close at $9.46. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 8.2% gain over the past four weeks.
Investor confidence in Teladoc’s upcoming third-quarter results and 2025 guidance fueled the double-digit surge. The company provided an early look at its estimated third-quarter results, with revenue expected to reach $626.4 million, surpassing the Zacks Consensus Estimate of $625 million and adjusted EBITDA at $69.9 million. Alongside the CFO transition, Teladoc reaffirmed its full-year 2025 revenue and adjusted EBITDA outlook issued on July 29, reinforcing management’s commitment to steady growth.
This telehealth services provider is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of -36.8%. Revenues are expected to be $625.2 million, down 2.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Teladoc, the consensus EPS estimate for the quarter has been revised 0.6% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TDOC going forward to see if this recent jump can turn into more strength down the road.
Teladoc is a member of the Zacks Medical Services industry. One other stock in the same industry, Avantor, Inc. (AVTR - Free Report) , finished the last trading session 0.4% lower at $15.4. AVTR has returned 31.2% over the past month.
For Avantor, the consensus EPS estimate for the upcoming report has changed -2.2% over the past month to $0.23. This represents a change of -11.5% from what the company reported a year ago. Avantor currently has a Zacks Rank of #4 (Sell).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teladoc (TDOC) Soars 10.0%: Is Further Upside Left in the Stock?
Teladoc (TDOC - Free Report) shares rallied 10% in the last trading session to close at $9.46. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 8.2% gain over the past four weeks.
Investor confidence in Teladoc’s upcoming third-quarter results and 2025 guidance fueled the double-digit surge. The company provided an early look at its estimated third-quarter results, with revenue expected to reach $626.4 million, surpassing the Zacks Consensus Estimate of $625 million and adjusted EBITDA at $69.9 million. Alongside the CFO transition, Teladoc reaffirmed its full-year 2025 revenue and adjusted EBITDA outlook issued on July 29, reinforcing management’s commitment to steady growth.
This telehealth services provider is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of -36.8%. Revenues are expected to be $625.2 million, down 2.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Teladoc, the consensus EPS estimate for the quarter has been revised 0.6% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TDOC going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Teladoc is a member of the Zacks Medical Services industry. One other stock in the same industry, Avantor, Inc. (AVTR - Free Report) , finished the last trading session 0.4% lower at $15.4. AVTR has returned 31.2% over the past month.
For Avantor, the consensus EPS estimate for the upcoming report has changed -2.2% over the past month to $0.23. This represents a change of -11.5% from what the company reported a year ago. Avantor currently has a Zacks Rank of #4 (Sell).